Supplementary Figure 9 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers

figure

posted on 2023-07-19, 14:20 authored by Taraswi Mitra Ghosh, Suman Mazumder, Joshua Davis, Jyoti Yadav, Ayuba Akinpelu, Ahmed Alnaim, Harish Kumar, Razan Waliagha, Allison E. Church Bird, Soroush Rais-Bahrami, R. Curtis Bird, Panagiotis Mistriotis, Amarjit Mishra, Clayton C. Yates, Amit K. Mitra, Robert D. Arnold

Supplementary Fig. 9 shows Fluorescent-Activated Cell Sorting CD44High: PC-3M cell line stained with stemness markers (CD44) and sorted CD44+ cells, followed by CONV-TOPO, METRO-TOPO, CONV-DTX, and combination (CONV-DTX+METRO-TOPO) therapy and cell cytotoxicity and caspase3/7 levels assessed A) Cytotoxicity profiling by MTT showed combination (CONV-DTX+METRO-TOPO) reduces cell survival compared with other treatments CONV-TOPO>CONV-DTX>METRO-TOPO B) AR-mCRPC- PC-3M showed combination (CONV-DTX+METRO-TOPO) reduces levels the most of apoptosis compared to other treatments (*p<0.05).

Funding

N/A

History

ARTICLE ABSTRACT

The utilization of metronomic-like dosing regimens of topotecan alone and in combination with DTX resulted in the suppression of makers associated with EMT and stem-like cell populations in AVPC models. The identification of molecular signatures and their potential to serve as novel biomarkers for monitoring treatment efficacy and disease progression response to treatment efficacy and disease progression were achieved using bulk RNA-seq and single-cell-omics methodologies.